Generex Biotechnology Corp. (OTC: GNBT) Interview with CEO Joe Moscato. Joe shares an update on the continued transformation of Generex into a next-generation integrated pharmaceutical healthcare business, through strategic acquisitions. Generex’s recent acquisition of medical services assets is generating over $75 million in revenues and is expect to generate over $1 billion annual revenues, as it expands to multiple states over the next 18 months.
Joe Moscato outlines the corporate growth strategy, which is focused on strategic acquisitions of revenue-generating healthcare assets, including: services, pharmaceuticals and medical devices, and maximizing shareholder value through spin-out’s and dividends.
Discussion also includes an update on Generex’s clinical-stage immuno-oncology assets, which are being developed in partnerships with Merck and Shenzhen BioScien, and address billion dollar market opportunities.
Investor Presentation